Guerbet

Company snapshot

Guerbet is a global leader in medical imaging, dedicated to improving patient care through innovation. With nearly a century of expertise, the company offers a comprehensive portfolio of pharmaceutical products, medical devices, and AI-driven solutions for diagnostic and interventional imaging. Guerbet invests 9% of its annual revenue in research and development, with dedicated innovation centers

• 4 active pipeline program(s) linked via ClinicalTrials.gov.
• 4 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Guerbet. Not investment advice.

• What is Guerbet?

  Guerbet is a pharma organization headquartered in VILLEPINTE, FR. Primary therapeutic focus areas include Primary Brain Tumor, Hepatocellular Carcinoma, Motor Function. NovaPharmaNews links 4 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from publi

• Is Guerbet publicly traded?

  Guerbet appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Guerbet develop or market?

  We link 5 drug profile(s) where Guerbet is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/guerbet#company-drugs.

• What are the latest developments for Guerbet?

  In the last 12 months our linked public records show 4 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Guerbet focus on?

  Guerbet focuses on Primary Brain Tumor, Hepatocellular Carcinoma, Motor Function based on our analysis of their pipeline programs and drug development activities.